Measurement of the Interleukin Family Member ST2 in Patients With Acute DyspneaResults From the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study
James L. Januzzi, Jr, MD FACC*,1,2,*,
W. Frank Peacock, MD ,1,
Alan S. Maisel, MD, FACC ,1,2,
Claudia U. Chae, MD, MPH, FACC*,
Robert L. Jesse, MD, FACC ,1,
Aaron L. Baggish, MD*,
Michelle O’Donoghue, MD*,
Rahul Sakhuja, MD*,
Annabel A. Chen, MD*,
Roland R.J. van Kimmenade, MD||,
Kent B. Lewandrowski, MD*,
Donald M. Lloyd-Jones, MD, MSc, FACC¶ and
Alan H.B. Wu, PhD#,1
* Department of Medicine and Laboratory Medicine, Massachusetts General Hospital, Boston, Massachusetts
Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
Department of Medicine, University of California, San Diego, California
# Department of Laboratory Medicine, University of California, San Francisco, California
Department of Medicine, Virginia Commonwealth University, Richmond, Virginia
|| Department of Medicine, University Hospital Maastricht, Maastricht, the Netherlands
¶ Department of Preventive Medicine and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 ST2 Concentrations at Presentation as a Function of Survival at 1 Year
Medians are depicted; boxes represent the 25th and 75th percentile, whereas whiskers represent the 5th and 95th percentile.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Receiver-Operating Characteristic Analysis for ST2 and Death at 1 Year
Receiver operating characteristic analysis with area under the curve (AUC) demonstrated for ST2 and death at 1 year after presentation with dyspnea. Candidate cut-points for ST2 are depicted. CI = confidence interval.
|
|
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Hazard Curves Depicting the Rates of Death From Presentation to 1 Year of Follow-Up
Among dyspneic patients with ST2 concentrations  0.20 ng/ml, a high rate of mortality was noted among those (A) with and (B) without acute heart failure (all log-rank p values <0.001).
|
|
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Mortality Rates at 1 Year as a Function of ST2 and NT-proBNP Concentrations
Mortality rates at 1 year as a function of ST2 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) concentrations among (A) dyspneic patients with and without acute heart failure (HF) (n = 593) as well as (B) those with acute HF (n = 208).
|
|
|
